首页|期刊导航|肿瘤药学|BRD4抑制剂抗肿瘤机制研究进展

BRD4抑制剂抗肿瘤机制研究进展

WU Fang ZHANG Yongchang LI Kunyan HENG Jianfu YANG Nong

肿瘤药学2019，Vol.9Issue(2)：177-183,7.

肿瘤药学2019，Vol.9Issue(2)：177-183,7.DOI:10.3969/j.issn.2095-1264.2019.02.01

BRD4抑制剂抗肿瘤机制研究进展

Advance in Anti-tumor Mechanism Study of Bromodomain-Containing Protein 4 Inhibitors

WU Fang ¹ZHANG Yongchang ²LI Kunyan ²HENG Jianfu ²YANG Nong²

作者信息

1. University of South China, Hengyang, Hunan, 421001, China
2. Hunan Cancer Hospital / The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South of China, Changsha, Hunan, 410013, China
折叠

摘要

Abstract

Bromodomain-containing protein 4 (BRD4) is the most important member of the bromodomain and extra-terminal (BET) family proteins. It is comprised of two conserved N-terminal bromodomains and an extraterminal domain. Many recent studies have shown the expression of BRD4 is associated with genesis and development of many kinds of cancers, such as lung cancer, breast cancer, acute myelogenous leukemia (AML) and hepatoma carcinoma. At present, small molecular compound targeting BRD4 have been developed and shown significantly antitumor efficacy. Different anti-tumor mechanisms of BRD4 inhibitors have also been found in different tumors. This review summarized the recent researches on the mechanism of BRD4 inhibitors on different types of cancers.

关键词

肿瘤/BRD4/BETi

Key words

Cancer/BRD4/BETi

分类

医药卫生

引用本文复制引用

WU Fang,ZHANG Yongchang,LI Kunyan,HENG Jianfu,YANG Nong..BRD4抑制剂抗肿瘤机制研究进展[J].肿瘤药学,2019,9(2):177-183,7.

基金项目

国家自然科学基金(81501992) （81501992）

湖南省自然科学基金(2017SK2134). （2017SK2134）

肿瘤药学

OACSTPCD

ISSN：2095-1264

访问量0

下载量0

段落导航